Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2006 1
2007 2
2008 1
2009 1
2010 2
2012 2
2013 1
2014 2
2015 4
2016 4
2017 13
2018 4
2019 6
2020 8
2021 8
2022 10
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Long-term follow-up of congenital hydronephrosis in a single-center study.
Morizawa Y, Aoki K, Fukui S, Tomizawa M, Shimizu T, Onishi K, Hori S, Gotoh D, Nakai Y, Miyake M, Torimoto K, Fujimoto K, Otani T, Fujimoto K. Morizawa Y, et al. Among authors: aoki k. Int J Urol. 2024 Jan 11. doi: 10.1111/iju.15391. Online ahead of print. Int J Urol. 2024. PMID: 38205874
Association between urine 6-sulfatoxy-melatonin level and intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer.
Miyake M, Nishimura N, Ohnishi S, Oda Y, Miyamoto T, Shimizu T, Hori S, Morizawa Y, Gotoh D, Nakai Y, Anai S, Torimoto K, Aoki K, Fujii T, Tanaka N, Fujimoto K. Miyake M, et al. Among authors: aoki k. Support Care Cancer. 2022 Jul;30(7):6145-6153. doi: 10.1007/s00520-022-07043-0. Epub 2022 Apr 14. Support Care Cancer. 2022. PMID: 35426045
Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World Data.
Miyake M, Nishimura N, Shimizu T, Ohnishi M, Kuwada M, Itami Y, Inoue T, Ohnishi K, Matsumoto Y, Yoshida T, Tatsumi Y, Shinohara M, Hori S, Morizawa Y, Gotoh D, Nakai Y, Anai S, Torimoto K, Aoki K, Fujii T, Tanaka N, Fujimoto K. Miyake M, et al. Among authors: aoki k. Cancer Manag Res. 2022 Feb 16;14:623-635. doi: 10.2147/CMAR.S348899. eCollection 2022. Cancer Manag Res. 2022. PMID: 35210859 Free PMC article.
Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma.
Miyake M, Shimizu T, Nishimura N, Kiba K, Maesaka F, Oda Y, Tachibana A, Tomizawa M, Ohmori C, Matsumura Y, Ichikawa K, Mizobuchi S, Yoshikawa T, Hori S, Morizawa Y, Gotoh D, Nakai Y, Anai S, Torimoto K, Aoki K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group. Miyake M, et al. Among authors: aoki k. Clin Genitourin Cancer. 2022 Apr;20(2):196.e1-196.e9. doi: 10.1016/j.clgc.2021.11.006. Epub 2021 Nov 15. Clin Genitourin Cancer. 2022. PMID: 34916166
61 results